CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) that target the PD-1/PD-L1 axis are the most commonly used immunotherapy in patients with non-small cell lung carcinoma (NSCLC) and are now approved as first-line treatment in several countries [3, 4].